Last reviewed · How we verify
NCT03875833
Prospective Analysis of Effect of Collagen Wrap Conduit on Radial and Ulnar Nerve Function Following Radial/Ulnar Forearm Free Flap Harvest
NA trial testing Collagen Nerve Wrap Conduit in Head and Neck Neoplasms. Withdrawn.
1 January 2024
Quick facts
| Lead sponsor | The University of Texas Health Science Center, Houston |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Start date | 9 October 2020 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 January 2024 |
Drugs / interventions tested
- Collagen Nerve Wrap Conduit
Conditions studied
- Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →
- Dysesthesia — all drugs for Dysesthesia →
Sponsor
The University of Texas Health Science Center, Houston
Who can join
18 and older, any sex, with Head and Neck Neoplasms or Dysesthesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether collagen nerve conduits placed on exposed radial and ulnar nerves during radial and ulnar forearm free flap harvests will reduce the occurrence and degree of sensory nerve deficit.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Modern Trends for Peripheral Nerve Repair and Regeneration: Beyond the Hollow Nerve Guidance Conduit.
Carvalho CR, Oliveira JM, Reis RL. · · 2019 · cited 201× · PMID 31824934 · DOI 10.3389/fbioe.2019.00337
Verify or expand the search:
- PubMed search for NCT03875833
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Neoplasms
Currently open trials in the same condition.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
- NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
- NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting
Other The University of Texas Health Science Center, Houston trials
Trials by the same sponsor.
- NCT04200729 — Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-cente · Phase 4 · not yet recruiting
- NCT07225062 — Improving HIV Prevention and Substance Use Post-Sexual Assault Services · NA · not yet recruiting
- NCT07396974 — Increasing Treatment Access in Trauma Exposed Children: Developing an Adapted Step One Intervention (RCT) · NA · not yet recruiting
- NCT07170163 — Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families · NA · not yet recruiting
- NCT06915441 — Lipid Infusions to Optimize Nutrition Trial · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03875833 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center, Houston
- Last refreshed: 22 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03875833.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing